Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia

Krützmann, Maria Eduarda; Martini, Ranieri Reichel; Guterres, Fernanda de Souza; Kohlrausch, Ramona; Wagner, Sandrine Comparsi; Mattevi, Vanessa Suñé; Torriani, Mayde Seadi; Fogliatto, Laura; Linden, Rafael; Antunes, Marina Venzon

doi:10.1016/j.jpba.2022.115108

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 121 Further, the degree of patient satisfaction concerning self‐collection and treatment adherence using VAMS has been evaluated on chronic myeloid leukaemia patients receiving imatinib mesylate therapy. 125 The study revealed that 87% of patients experienced less discomfort with VAMS sampling than with conventional sampling but only 77% of patient‐collected samples met the quality criteria.…”

Section: Applicationsmentioning

confidence: 97%

“…Zimmerman et al determined 10 TKIs, where nine TKIs exhibited a constant conversion factor over their entire calibration range with only trametinib exhibiting a decreasing conversion factor with increasing VAMS concentration 121 . Further, the degree of patient satisfaction concerning self‐collection and treatment adherence using VAMS has been evaluated on chronic myeloid leukaemia patients receiving imatinib mesylate therapy 125 . The study revealed that 87% of patients experienced less discomfort with VAMS sampling than with conventional sampling but only 77% of patient‐collected samples met the quality criteria.…”

Section: Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Blood microsampling technologies: Innovations and applications in 2022

Thangavelu

Wouters

Kindt

et al. 2023

Analytical Science Advances

View full text Add to dashboard Cite

With the development of highly sensitive bioanalytical techniques, the volume of samples necessary for accurate analysis has reduced. Microsampling, the process of obtaining small amounts of blood, has thus gained popularity as it offers minimal‐invasiveness, reduced logistical costs and biohazard risks while simultaneously showing increased sample stability and a potential for the decentralization of the approach and at‐home self‐sampling. Although the benefits of microsampling have been recognised, its adoption in clinical practice has been slow. Several microsampling technologies and devices are currently available and employed in research studies for various biomedical applications. This review provides an overview of the state‐of‐the‐art in microsampling technology with a focus on the latest developments and advancements in the field of microsampling. Research published in the year 2022, including studies (i) developing strategies for the quantitation of analytes in microsamples and (ii) bridging and comparing the interchangeability between matrices and choice of technology for a given application, is reviewed to assess the advantages, challenges and limitations of the current state of microsampling. Successful implementation of microsampling in routine clinical care requires continued efforts for standardization and harmonization. Microsampling has been shown to facilitate data‐rich studies and a patient‐centric approach to healthcare and is foreseen to play a central role in the future digital revolution of healthcare through continuous monitoring to improve the quality of life.

show abstract

Section: Applicationsmentioning

confidence: 97%

Section: Applicationsmentioning

confidence: 99%

Blood microsampling technologies: Innovations and applications in 2022

Thangavelu

Wouters

Kindt

et al. 2023

Analytical Science Advances

View full text Add to dashboard Cite

show abstract

“…However, VAMS would be very useful, especially for abiraterone, which has poor stability. 8,18,19,[22][23][24][25][26] The aim of this study was to develop and validate a UHPLC-MS/MS quantitation method for the TDM of abiraterone, alectinib, cabozantinib, imatinib, olaparib, and sunitinib, and the metabolites, D(4)-abiraterone (D4A), alectinib-M4, imatinib-M1, and N-desethyl sunitinib, using VAMS devices.…”

Section: Introductionmentioning

confidence: 99%

“…However, VAMS would be very useful, especially for abiraterone, which has poor stability. 8,18,19,22–26…”

Section: Introductionmentioning

confidence: 99%

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites

Meertens,

de Vries,

Rosing

et al. 2024

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

Background: Volumetric Absorptive Microsampling (VAMS) is a useful tool for therapeutic drug monitoring (TDM) of oral targeted anticancer agents. VAMS aims to improve safety and efficacy by enabling at-home blood sample collection by patients. This study aimed to develop and validate an ultra-high performance liquid chromatography–tandem mass spectrometry method for the quantitative determination of abiraterone, alectinib, cabozantinib, imatinib, olaparib, sunitinib, and the metabolites, Δ(4)-abiraterone (D4A), alectinib-M4, imatinib-M1, and N-desethyl sunitinib, in dried whole blood samples using VAMS to support TDM. Methods: After the collection of 10 μL of whole blood sample using the VAMS device, the analytes were extracted from the tip using methanol with shaking, evaporated, and reconstituted in acetonitrile:0.1 mol/L ammonium hydroxide in water (1:1, vol/vol). The extracts were then analyzed using ultra-high performance liquid chromatography–tandem mass spectrometry. Validation experiments based on the ICH M10 guideline were carried out, and stability was evaluated under shipping and storage conditions. VAMS specimens were collected in the outpatient clinic to demonstrate the applicability of the assay. Results: The validated range of the method was considered accurate and precise for all analytes. Accordingly, the validation experiments met the relevant requirements, except for cross-analyte interference. Based on the stability data, shipment can be performed at room temperature within 14 days after sample collection and the VAMS specimen can be stored up to 9 months at −20 and −70°C. Samples from 59 patients were collected at the hospital. Conclusions: The developed method could be used to successfully quantify the concentrations of abiraterone, D4A, alectinib, alectinib-M4, cabozantinib, imatinib, imatinib-M1, olaparib, sunitinib, and N-desethyl sunitinib within the validated range using VAMS. Therefore, the method can be used to estimate the dried whole blood-to-plasma ratios for TDM in the clinic.

show abstract